An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature

Table 1

Concomitant multiple myeloma and chronic myeloid leukemia cases.

Pt	Age/Sex	Year	First disease	Diagnosis interval (month)	Type of M-protein	Therapy for MM	Therapy for CML	Confirmation method of Ph+	Type of Ph	Reference
1	77M	1972	MM	33	BJP	No treatment	No treatment	Chr		MacSween and Langley [3]
2	65/F	1974	CML	113	IgG-κ	No treatment	Busulfan	Chr		Derghazarian and Whittemore [4]
3	58/M	1982	MM and CML	Simultaneous	IgG-κ	MP, RT	HU, Busulfan,	Chr		Boots and Pegrum [5]
4	71/M	1993	MM	24	IgG-κ	MP, RT	HU	Chr		Klenn et al. [6]
5	72/F	1998	MM and CML	Simultaneous	IgG-κ	VP	IFN-α	Chr, PCR, FISH	P210	Tanaka et al. [7]
6	70/M	1999	MM	33	IgG-κ	Not reported	Not reported	Chr		Nitta et al. [8]
7	81/M	2001	MM and CML	Simultaneous	IgA-κ	MP	No treatment	Chr, PCR		Alvarez-Larrán et al. [9]
8	66/M	2003	MM and CML	Simultaneous	IgG-κ	MP	INF-α, HU, Busulfan	Chr, PCR, FISH	P210	Schwarzmeier et al. [10]
9	47/M	2003	MM	33	BJP	LOAD-IN	Not reported	Chr		Nakagawa [11]
10	68/M	2005	CML	20	IgG-λ	MP	IFN-α, imatinib	Chr, PCR	P210	Garipidou et al. [12]
11	85/F	2005	MM and CML	Simultaneous	IgG-λ	Not reported	Not reported	Chr, PCR	P210	Wakayama et al. [13]
12	76/M	2009	CML	14	IgA-κ	MP	IFN-α, imatinib	Chr, PCR, FISH	P210	Galanopoulos et al. [14]
13	57/F	2009	CML	65	IgA-κ	TD, VAD	Imatinib	Chr, PCR	P210	Michael et al. [15]
14	72/F	2010	CML	3	IgG-κ	No treatment	Imatinib	Chr, PCR	P210	Ide et al. [16]
15	71/F	2012	MM and CML	Simultaneous	IgG-κ	MP, Bd, Ld	Imatinib	Chr		Offiah et al. [17]
16	64/F	2013	MM and CML	Simultaneous	IgA-κ	BD	Imatinib	Chr		Romanenko et al. [18]
17	62/F	2013	MM	17	IgG-κ	RT, VCD, VCDD, VRD	Dasatinib	Chr, PCR	P210	Ragupathi et al. [19]
18	77/M	2014	MM and CML	Simultaneous	IgG-κ	RT, BD	No treatment	Chr, PCR	P210	Maerki et al. [20]
19	60/M	2014	MM	48	IgG-κ	RT, Ld	HU, dasatinib	Chr, FISH		Alsidawi et al. [21]
20	63/F	2012	CML	120	IgG-κ	BD, Ld	Imatinib	Chr, PCR	P210	Pessach et al. [22]
21	68/M	2012	MM	54	IgG-λ	VAD	Imatinib	Chr, PCR	P210	Pessach et al. [22]
22	76/M	2015	CML	38	IgA-λ	No treatment	Imatinib	Chr, PCR		Ahn et al. [23]
23	51/F	2016	MM	Unknown	IgG	BD	Imatinib	Chr, PCR		Wolleschak and Heidel [24]
24	88/M	2016	MM and CML	Simultaneous	IgD-κ	VRD	Imatinib	Chr		Ali et al. [25]
25	76/M	2018	MM	28	IgG-κ	Ld	Dasatinib, bosutinib	Chr, PCR, FISH	P190	Our case

BJP, Bence Jones protein; MP, melphalan, prednisolone; RT, radiation therapy; HU, hydroxyurea; LOAD-IN, melphalan, ranimustine, vincristine, IFN-α; PSL, prednisolone; VCD, bortezomib, cyclophosphamide, dexamethasone; VCDD, VCD plus doxorubicin; VRD, bortezomib, lenalidomide, dexamethasone; Ld, lenalidomide, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; BD, bortezomib, dexamethasone; CBD, BD plus cyclophosphamide; Rd, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; Chr, chromosome; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization.